STAGE III PANCREATIC CANCER AJCC V6 AND V7
Clinical trials for STAGE III PANCREATIC CANCER AJCC V6 AND V7 explained in plain language.
Never miss a new study
Get alerted when new STAGE III PANCREATIC CANCER AJCC V6 AND V7 trials appear
Sign up with your email to follow new studies for STAGE III PANCREATIC CANCER AJCC V6 AND V7, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New cocktail of drugs and supplements targets Hard-to-Treat pancreatic cancer
Disease control OngoingThis early-phase study is testing a mix of two chemotherapy drugs (gemcitabine and Abraxane), a diabetes drug (metformin), and a special dietary supplement in people with pancreatic cancer that cannot be removed by surgery. The main goal is to see if this combination is safe and …
Matched conditions: STAGE III PANCREATIC CANCER AJCC V6 AND V7
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 01, 2026 15:57 UTC
-
New cocktail of cancer drugs shows promise in early pancreatic cancer trial
Disease control OngoingThis early-phase study tested a combination of three drugs (gemcitabine, dasatinib, and erlotinib) in 19 people with advanced pancreatic cancer that had spread or couldn't be surgically removed. The main goal was to find the safest dose and see how well patients tolerated the tre…
Matched conditions: STAGE III PANCREATIC CANCER AJCC V6 AND V7
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 30, 2026 15:52 UTC
-
New drug cocktail shows promise against tough cancers
Disease control OngoingThis study tested a combination of two drugs, cediranib and olaparib, in 122 people with advanced or spreading solid tumors, including certain breast, lung, and pancreatic cancers. The goal was to see if the combo could shrink tumors by blocking enzymes that help cancer grow and …
Matched conditions: STAGE III PANCREATIC CANCER AJCC V6 AND V7
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 30, 2026 15:48 UTC
-
New drug combo targets Hard-to-Treat cancers in early trial
Disease control OngoingThis early-phase study tests two drugs together—guadecitabine and durvalumab—in people with advanced liver, pancreatic, bile duct, or gallbladder cancers that have spread. The goal is to find the safest dose and see if the combination can shrink tumors. About 55 adults with these…
Matched conditions: STAGE III PANCREATIC CANCER AJCC V6 AND V7
Phase: PHASE1 • Sponsor: University of Southern California • Aim: Disease control
Last updated Apr 29, 2026 15:01 UTC
-
New drug combo aims to boost Radiation's punch against tough GI cancers
Symptom relief OngoingThis early-phase study tests an oral drug called ropidoxuridine (IPdR) in people with advanced gastrointestinal cancers that cannot be cured. The drug is designed to make tumor cells more sensitive to radiation therapy. Researchers aim to find the safest dose and see how well the…
Matched conditions: STAGE III PANCREATIC CANCER AJCC V6 AND V7
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Symptom relief
Last updated May 01, 2026 16:01 UTC